BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $2.31 billion. The enterprise value is $2.84 billion.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, before market open.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 209.25 million shares outstanding. The number of shares has increased by 5.50% in one year.
| Current Share Class | 209.25M |
| Shares Outstanding | 209.25M |
| Shares Change (YoY) | +5.50% |
| Shares Change (QoQ) | +3.80% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 85.02% |
| Float | 207.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 39.37 |
| PS Ratio | 4.55 |
| Forward PS | 3.82 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.65 |
| EV / EBITDA | 75.90 |
| EV / EBIT | 82.60 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93
| Current Ratio | 2.93 |
| Quick Ratio | 2.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | 20.87 |
| Debt / FCF | n/a |
| Interest Coverage | 0.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.54% |
| Return on Invested Capital (ROIC) | 5.71% |
| Return on Capital Employed (ROCE) | 10.12% |
| Revenue Per Employee | $868,078 |
| Profits Per Employee | -$92,190 |
| Employee Count | 580 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 9.82 |
Taxes
In the past 12 months, BCRX has paid $2.29 million in taxes.
| Income Tax | 2.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +62.59% in the last 52 weeks. The beta is 1.10, so BCRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +62.59% |
| 50-Day Moving Average | 8.98 |
| 200-Day Moving Average | 8.14 |
| Relative Strength Index (RSI) | 65.01 |
| Average Volume (20 Days) | 4,701,676 |
Short Selling Information
The latest short interest is 20.98 million, so 10.03% of the outstanding shares have been sold short.
| Short Interest | 20.98M |
| Short Previous Month | 18.30M |
| Short % of Shares Out | 10.03% |
| Short % of Float | 10.13% |
| Short Ratio (days to cover) | 3.22 |
Income Statement
In the last 12 months, BCRX had revenue of $503.49 million and -$53.47 million in losses. Loss per share was -$0.26.
| Revenue | 503.49M |
| Gross Profit | 323.48M |
| Operating Income | 34.44M |
| Pretax Income | -146.50M |
| Net Income | -53.47M |
| EBITDA | 37.47M |
| EBIT | 34.44M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $295.09 million in cash and $829.29 million in debt, giving a net cash position of -$534.20 million or -$2.55 per share.
| Cash & Cash Equivalents | 295.09M |
| Total Debt | 829.29M |
| Net Cash | -534.20M |
| Net Cash Per Share | -$2.55 |
| Equity (Book Value) | -451.93M |
| Book Value Per Share | -2.16 |
| Working Capital | 270.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.85 million and capital expenditures -$1.03 million, giving a free cash flow of -$26.89 million.
| Operating Cash Flow | -25.85M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -26.89M |
| FCF Per Share | -$0.13 |
Full Cash Flow StatementMargins
Gross margin is 64.25%, with operating and profit margins of 6.84% and -10.62%.
| Gross Margin | 64.25% |
| Operating Margin | 6.84% |
| Pretax Margin | -10.17% |
| Profit Margin | -10.62% |
| EBITDA Margin | 7.44% |
| EBIT Margin | 6.84% |
| FCF Margin | n/a |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.50% |
| Shareholder Yield | -5.50% |
| Earnings Yield | -2.31% |
| FCF Yield | -1.16% |
Dividend DetailsAnalyst Forecast
The average price target for BCRX is $16.75, which is 51.72% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.75 |
| Price Target Difference | 51.72% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 16.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -2.24 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.24 |
| Piotroski F-Score | 5 |